International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.

  title={International collaboration to assess the risk of Guillain Barr{\'e} Syndrome following Influenza A (H1N1) 2009 monovalent vaccines.},
  author={Caitlin N Dodd and S. Romio and S. Black and C. Vellozzi and N. Andrews and M. Sturkenboom and P. Zuber and W. Hua and J. Bonhoeffer and J. Buttery and N. Crawford and G. Deceuninck and C. D. de Vries and P. De Wals and M. Guti{\'e}rrez-Gimeno and H. Heijbel and Hayley A. Hughes and K. Hur and A. Hviid and J. Kelman and Tehri Kilpi and S. K. Chuang and K. Macartney and M. Rett and Vesta Richardson Lopez-Callada and Daniel Salmon and F. Gim{\'e}nez-S{\'a}nchez and N. Sanz and B. Silverman and J. Storsaeter and Umapathi Thirugnanam and N. V. D. van der Maas and Katherine Yih and Tao Zhang and H. Izurieta},
  volume={31 40},
  • Caitlin N Dodd, S. Romio, +32 authors H. Izurieta
  • Published 2013
  • Medicine
  • Vaccine
  • BACKGROUND The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain-Barré syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the… CONTINUE READING

    Tables and Topics from this paper.


    Publications referenced by this paper.
    Guillain-Barré syndrome following influenza vaccination.
    • 229
    • Open Access